Zacks Research Has Positive Outlook of PAHC FY2026 Earnings

Phibro Animal Health Corporation (NASDAQ:PAHC) – Analysts at Zacks Research boosted their FY2026 earnings per share (EPS) estimates for Phibro Animal Health in a research note issued on Thursday, June 11th. Zacks Research analyst Team now forecasts that the company will post earnings of $3.05 per share for the year, up from their prior forecast of $3.04. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Phibro Animal Health’s current full-year earnings is $3.07 per share. Zacks Research also issued estimates for Phibro Animal Health’s Q4 2026 earnings at $0.69 EPS, Q1 2027 earnings at $0.79 EPS, Q2 2027 earnings at $0.85 EPS, Q3 2027 earnings at $0.76 EPS, FY2027 earnings at $3.18 EPS, Q1 2028 earnings at $0.82 EPS, Q3 2028 earnings at $0.82 EPS and FY2028 earnings at $3.35 EPS.

Phibro Animal Health (NASDAQ:PAHC) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.76 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.04. Phibro Animal Health had a return on equity of 37.14% and a net margin of 6.35%.The business had revenue of $383.54 million during the quarter, compared to analysts’ expectations of $367.02 million. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS.

A number of other equities research analysts have also recently commented on the company. Weiss Ratings cut Phibro Animal Health from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, May 8th. Citigroup decreased their price target on shares of Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating for the company in a report on Thursday, May 14th. Finally, Wall Street Zen lowered shares of Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Two equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $38.80.

Phibro Animal Health Stock Up 0.3%

Shares of Phibro Animal Health stock opened at $31.26 on Friday. The company has a quick ratio of 1.26, a current ratio of 3.17 and a debt-to-equity ratio of 1.97. Phibro Animal Health has a 12 month low of $23.57 and a 12 month high of $60.08. The business has a fifty day simple moving average of $44.35 and a 200 day simple moving average of $44.86. The stock has a market cap of $1.27 billion, a PE ratio of 13.42, a price-to-earnings-growth ratio of 0.47 and a beta of 0.46.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of PAHC. Millennium Management LLC grew its stake in Phibro Animal Health by 4,227.1% in the 4th quarter. Millennium Management LLC now owns 641,313 shares of the company’s stock valued at $23,959,000 after buying an additional 626,492 shares during the last quarter. JPMorgan Chase & Co. raised its position in Phibro Animal Health by 1,730.9% in the third quarter. JPMorgan Chase & Co. now owns 238,115 shares of the company’s stock valued at $9,634,000 after purchasing an additional 225,110 shares during the last quarter. Allspring Global Investments Holdings LLC raised its position in Phibro Animal Health by 145.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 286,172 shares of the company’s stock valued at $15,671,000 after purchasing an additional 169,628 shares during the last quarter. Castleark Management LLC bought a new position in Phibro Animal Health in the first quarter valued at about $7,904,000. Finally, Advisors Preferred LLC bought a new position in Phibro Animal Health in the third quarter valued at about $3,953,000. Institutional investors and hedge funds own 99.34% of the company’s stock.

Insider Buying and Selling

In other Phibro Animal Health news, CEO Jack Bendheim sold 4,528 shares of the business’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $48.49, for a total transaction of $219,562.72. Following the sale, the chief executive officer directly owned 56,152 shares of the company’s stock, valued at $2,722,810.48. The trade was a 7.46% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 69,648 shares of company stock worth $3,759,028. Insiders own 50.13% of the company’s stock.

Phibro Animal Health Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 24th. Shareholders of record on Wednesday, June 3rd will be given a dividend of $0.12 per share. The ex-dividend date of this dividend is Wednesday, June 3rd. This represents a $0.48 annualized dividend and a yield of 1.5%. Phibro Animal Health’s payout ratio is 20.60%.

Phibro Animal Health News Summary

Here are the key news stories impacting Phibro Animal Health this week:

• Positive Sentiment: Higher near-term and longer-term earnings estimates may signal improving fundamentals and can be viewed favorably by investors. Is PAHC Undervalued at 10x Earnings vs Peers?
• Neutral Sentiment: FY2026 EPS was nudged up to $3.05 from $3.04, still roughly in line with the broader consensus of $3.07, so the change is incremental rather than a major surprise.
• Neutral Sentiment: Zacks also slightly lifted estimates for Q4 2026, Q1 2027, Q2 2027, Q3 2027, Q1 2028, Q3 2028, FY2027, and FY2028, reinforcing a steadier earnings outlook without changing the firm’s Hold stance.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.